Author disclosures: R. Marshall Austin, MD, PhD, has served as a consultant and/or speaker without accepting personal compensation for AutoCyte Inc., Cytyc Corporation, Digene Corporation, Morphometrix Technologies Inc., NeoPath, Inc., Neuromedical Sciences Inc., and Veracel Inc. J. Thomas Cox, MD, has consulted for Cytyc Corporation, Digene Corporation, 3M Pharmaceuticals, Inc., and Merck & Co., Inc., and is on the speaker's bureau of Cytyc Corporation, and 3M Pharmaceuticals, Inc. Jack Cuzick, PhD, is a consultant to Digene Corporation. Eduardo Franco, MPH, DrPH, has occasionally been invited by 3M Pharmaceuticals, Inc., GlaxoSmithKline, Digene Corporation, and F. Hoffmann-La Roche Ltd. to serve as a temporary consultant or visiting speaker. Walter Kinney, MD, has received research support from 3M Pharmaceuticals and serves on the speaker's bureau for Cytyc Corporation and Digene Corporation. Evan Myers, MD, MPH, has received research support from and is a consultant to Merck Research Laboratories. Ellen Sheets, MD, was appointed as a vice president of Cytyc Corporation in May 2002, following the ACS guideline workshop. Thomas C. Wright, Jr., MD, has received research support from Digene Corporation and Cytyc Corporation and is on the speaker's bureau of Cytyc Corporation and TriPath Imaging, Inc.
American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer†
Version of Record online: 23 FEB 2009
Copyright © 2002 American Cancer Society
CA: A Cancer Journal for Clinicians
Volume 52, Issue 6, pages 342–362, November/December 2002
How to Cite
Saslow, D., Runowicz, C. D., Solomon, D., Moscicki, A.-B., Smith, R. A., Eyre, H. J. and Cohen, C. (2002), American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. CA: A Cancer Journal for Clinicians, 52: 342–362. doi: 10.3322/canjclin.52.6.342
This article is available online at http://CAonline.AmCancerSoc.org
- Issue online: 23 FEB 2009
- Version of Record online: 23 FEB 2009
An update to the American Cancer Society (ACS) guideline regarding screening for the early detection of cervical neoplasia and cancer, based on recommendations from a formal review and recent workshop, is presented. The new screening recommendations address when to begin screening, when screening may be discontinued, whether to screen women who have had a hysterectomy, appropriate screening intervals, and new screening technologies, including liquid-based cytology and HPV DNA testing.